Cytomegalovirus Treatment Market Size

Cytomegalovirus Treatment Market Analysis

The Cytomegalovirus (CMV) Treatment Market is anticipated to register a CAGR of 6.1% during the forecast period.

COVID-19 significantly impacted the cytomegalovirus treatment market during the pandemic period. The patients with cytomegalovirus infection were more prone to COVID-19 than the patients without the infection, thereby impacting the demand for treatment during the COVID-19 outbreak. For instance, the article published in the Journal of Medical Virology published in October 2021 mentioned that patients with cytomegalic virus infection might have presented with more severe COVID-19 upon admission to healthcare centers than those without the infections. Such a high risk of cytomegalovirus is expected to have a notable impact on the market's growth over the forecast period. However, the reduction of COVID-19 cases in the post-pandemic period is expected to contribute to the growth of the market owing to the rising focus on the development of advanced treatments for cytomegalovirus, thereby boosting the market growth over the forecast period.

The rising prevalence of CMV retinitis and congenital CMV infection, extending the application range of CMV treatment, increasing initiatives for creating awareness regarding treatments and diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.

For instance, as per the CDC data updated in May 2022, in the United States, around 150 infants are born with cytomegalovirus infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult. As per the same source, cytomegalovirus infection and the risk of reactivation of cytomegalovirus infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is expected to drive the demand for effective treatment options, thereby contributing to the market's growth.

In addition, the increasing prevalence of viral infections among AIDS patients due to weakened immune systems is expected to drive the demand for cytomegalovirus drugs. For instance, according to the WHO updates from November 2022, an estimated 38.4 million people were living with HIV, with 36.7 million adults and 1.7 million children affected with HIV in 2021. Since one of the most common Opportunistic Infections (OIs) documented in people with human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is Cytomegalovirus (CMV), the demand for cytomegalovirus treatment is anticipated to grow over the coming years.

Furthermore, the rising product approvals and product developments by various key market players are also expected to drive the market's growth in the forecast period. For instance, in May 2022, Hologic, Inc. announced that the US FDA approved its Aptima CMV Quant assay to quantify the viral load of Cytomegalovirus (CMV) in patients with solid organ or stem cell transplants. Similarly, in October 2021, Moderna, Inc. announced the first participant had been dosed in the Phase III pivotal registration study of mRNA-1647, the company's Cytomegalovirus (CMV) vaccine candidate. This study is known as CMVictory.

However, adverse effects and risks related to cytomegalovirus drugs may hamper the demand for the Cytomegalovirus (CMV) Treatment Market.